In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia's Prana Charging Into Confirmatory Trials For Alzheimer's Drug That Looks To Alter Disease

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Melbourne-headquartered biotech Prana is gearing up to begin confirmatory trials for its lead molecule PBT2, an Alzheimer's disease treatment that has demonstrated surprising ability to reverse dementia symptoms

You may also be interested in...



Australia’s Prana Misses Primary Endpoint In POC Alzheimer’s Disease Trial; Stock Tanks

Prana’s lead Alzheimer’s candidate fails both primary and secondary endpoints in Alzheimer’s proof-of-concept- trial, but the company still has hopes that an extension study will show a stronger signal.

Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come

Australia’s Prana Biotechnology has Phase II clinical trial data on a potential Huntington’s disease therapy to sustain a surge in the share price over the past year with more possibly on the way for an Alzheimer’s therapy.

Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop

The drug's inability to show an efficacy benefit highlights risks of Alzheimer's disease drug development and pressures Pfizer to pull off some pipeline wins.

Related Content

UsernamePublicRestriction

Register

SC075559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel